1.	PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Phase: Phase III Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: 9267-01, 2001-034, NCT00221702
2.	Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181065, NCT00267748
3.	Phase I Study of Azacitidine and Interferon alfa-2b in Patients With Unresectable Stage III or IV Melanoma or Unresectable Stage IV Renal Cell Carcinoma Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: YALE-HIC-27409, 7317, NCI-7317, NCT00217542
4.	Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: METRO1/IPC2005-001, NCT00908869
5.	Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EPROST-20070805, SCCC-2007055, NCT00854581